Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00919503 |
|
Recruitment Status :
Completed
First Posted : June 12, 2009
Results First Posted : August 13, 2021
Last Update Posted : August 13, 2021
|
Sponsor:
Fred Hutchinson Cancer Center
Collaborators:
medac GmbH
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Lauri Burroughs, Fred Hutchinson Cancer Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase II clinical trial studies how well treosulfan and fludarabine phosphate with or without low dose radiation before donor stem cell transplantation works in treating patients with nonmalignant (noncancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (noncancerous) diseases such as primary immunodeficiency disorders, bone marrow failure syndromes, hemoglobinopathies, and inborn errors of metabolism (metabolic disorders). Powerful chemotherapy drugs and/or radiation are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which doesn't work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient's disease, many hematopoietic cell transplantation regimens use intensive chemotherapy and/or radiation which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan and fludarabine phosphate) with or without low dose radiation results in new blood-forming cells (engraftment) of the new donor cells without increased toxicities in patients with nonmalignant (noncancerous) diseases.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-Neoplastic Hematologic and Lymphocytic Disorder | Procedure: Allogeneic Bone Marrow Transplantation Biological: Anti-Thymocyte Globulin Drug: Cyclosporine Drug: Fludarabine Phosphate Other: Laboratory Biomarker Analysis Drug: Methotrexate Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation Drug: Treosulfan Procedure: Umbilical Cord Blood Transplantation | Phase 2 |
OUTLINE:
CONDITIONING REGIMEN: Patients receive treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 1 hour on days -6 to -2. Patients receive anti-thymocyte globulin IV over 4-6 hours on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.
TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood (UCB) from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.
IMMUNOSUPPRESSION: Patients receive a combination of immunosuppressive medications to try and prevent graft-versus-host disease. There are 2 regimens depending on the donor.
Regimen A: Patients undergoing bone marrow or PBSC transplantation receive tacrolimus daily from day -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
Regimen B: Patients undergoing UCB transplantation receive cyclosporine on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil on days 0 to 40 followed by a taper until day 96 in the absence of GVHD.
After completion of study treatment, patients are followed up periodically for 5 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 98 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen |
| Actual Study Start Date : | July 31, 2009 |
| Actual Primary Completion Date : | June 10, 2020 |
| Actual Study Completion Date : | June 10, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome
MedlinePlus related topics:
Organ Donation
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Regimen A (PBSCT and BMT)
CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1. TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status. Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11. |
Procedure: Allogeneic Bone Marrow Transplantation
Infused IV
Other Names:
Biological: Anti-Thymocyte Globulin Given IV
Other Names:
Drug: Fludarabine Phosphate Given IV
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Methotrexate Given IV
Other Names:
Procedure: Peripheral Blood Stem Cell Transplantation Infused IV
Other Names:
Drug: Tacrolimus Given IV or PO
Other Names:
Drug: Treosulfan Given IV
Other Names:
|
|
Experimental: Regimen B (UBCT)
CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 . TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status. Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD. |
Biological: Anti-Thymocyte Globulin
Given IV
Other Names:
Drug: Cyclosporine Given IV or PO
Other Names:
Drug: Fludarabine Phosphate Given IV
Other Names:
Other: Laboratory Biomarker Analysis Correlative studies Drug: Mycophenolate Mofetil Given IV or PO
Other Names:
Radiation: Total-Body Irradiation Undergo total body irradiation
Other Names:
Drug: Treosulfan Given IV
Other Names:
Procedure: Umbilical Cord Blood Transplantation Single or double unit umbilical cord blood transplant, infused IV
Other Names:
|
Primary Outcome Measures :
- Preliminary Efficacy [ Time Frame: 1 year following transplant ]Number of patients engrafted (>5% donor CD3+ peripheral blood chimerisms) at 1 year following transplant
Secondary Outcome Measures :
- Non-relapse Mortality [ Time Frame: 1 year following transplant ]Number of patients who experienced non-relapse mortality by 1 year following transplant
- Number of Patients With Grade II-IV Acute Graft-versus-host Disease [ Time Frame: Day 100 post transplant ]Number of patients diagnosed with overall grade II-IV acute GVHD by Day 100 post transplant
- Number of Patients With of Chronic Graft-versus-host Disease [ Time Frame: 1 year following transplant ]Number of patients diagnosed with chronic GVHD and requiring systemic immunosuppression within 1 year following transplant
- Donor Chimerism CD3 at 100 Days Post Transplant [ Time Frame: Day 100 post transplant ]Number of patients with peripheral blood donor chimerism for CD3 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.
- Disease Response at One Year Following Hematopoietic Cell Transplantation [ Time Frame: 1 year following transplant ]Number of patients with no evidence of disease at one year following transplant
- Immune Reconstitution Following Hematopoietic Cell Transplantation [ Time Frame: 1 year following transplant ]Number of patients with immune reconstitution (defined by a normal range CD3) at 1 year post transplant
- Number of Participants With Infections [ Time Frame: 100 days post transplant ]Number of participants with clinically significant infections (bacterial, fungal, viral) requiring treatment within 100 days following transplant
- Overall Survival [ Time Frame: 1 year following transplant ]Number of patients alive at 1 year following transplant
- Donor Chimerism CD33 at Day 100 Post Transplant [ Time Frame: 100 days post transplant ]Number of patients with peripheral blood donor chimerism for CD33 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 49 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with a nonmalignant disease treatable by allogeneic HCT
- Patients with a known nonmalignant disease that is not clearly defined will need to be discussed with the protocol principal investigator (PI) (Dr. Lauri Burroughs) and potentially the nonmalignant board to determine if they are eligible for HCT on this study
- DONOR: Human leukocyte antigens (HLA)-identical related donors or unrelated donors matched for HLA-A, B, C, DRB1, and DQB1 or mismatched for a single allele at HLA-A, B, C, DRB1 or a single DQB1 antigen or allele mismatch by high resolution deoxyribonucleic acid (DNA) typing
- DONOR: PBSC is the preferred cell source (when feasible) for fully matched donors; PBSC may also be used for a mismatched donor following discussion with the PI; bone marrow is allowed when PBSC is not feasible or as determined by the PI
- DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and stored; the HLA-matched sibling bone marrow and cord blood would be matched for HLA-A, B, C, DRB1, and DQB1
- DONOR: Unrelated Umbilical Cord Blood: Unit selection is based on the cryopreserved total nucleated cell (TNC) dose and matching at HLA-A, B antigen level and DRB1 allele level typing; while HLA-C antigen/allele level typing is not considered in the matching criteria, if available, may be used to optimize unit selection
- DONOR: Unrelated Umbilical Cord Blood: The patient and the cord blood unit(s) must be matched for at least 4 of 6 loci as defined above
- DONOR: Unrelated Umbilical Cord Blood: Selection of two umbilical cord blood (UCB) units is allowed to provide sufficient cell dose
- DONOR: Unrelated Umbilical Cord Blood: The UCB unit with the least HLA disparity (with the patient) will be selected first (i.e., selection priority is 6/6 match > 5/6 match> 4/6 match); additional UCB units then may be selected to achieve the required cell dose; if a second unit is required, this unit will be the unit that most closely HLA matches the patient and meets minimum size criteria outlined below of at least 1.5 x 10^7 TNC/kg (i.e. a smaller more closely matched unit will be selected over a larger less well matched unit as long as minimum criteria are met)
- DONOR: Unrelated Umbilical Cord Blood: Each UCB unit MUST contain at least 1.5 x 10^7 TNC per kilogram recipient weight
- DONOR: Unrelated Umbilical Cord Blood: The total cell dose of the combined units must be at least 3.0 x 10^7 TNC per kilogram recipient weight
Exclusion Criteria:
- Patients with idiopathic aplastic anemia and Fanconi anemia; (patients with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria [PNH] or inherited marrow failure syndromes, except Fanconi anemia, will be allowed)
- Patients with impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
- Patients with impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (DLCO) < 50% of predicted (or, if unable to perform pulmonary function tests, then oxygen [O2] saturation < 92% on room air)
- Patients with impaired renal function as evidenced by creatinine-clearance < 50% for age, weight, height or serum creatinine > 2 x upper normal limit or dialysis-dependent
- Patients with evidence of synthetic dysfunction or severe cirrhosis requiring deferral of conditioning as recommended by a gastroenterology specialist
- Patients with an active infectious disease requiring deferral of conditioning; as recommended by an infectious disease specialist
- Patients who are positive for human immunodeficiency virus (HIV)
- Females who are pregnant or breast-feeding
- Patients with a known hypersensitivity to treosulfan and/or fludarabine
- Receiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PI
- DONOR: Deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis
- DONOR: HIV-positive
- DONOR: With active infectious hepatitis
- DONOR: Females with a positive pregnancy test
- DONOR: HLA-matched sibling cord blood exclusions: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by the National Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
- DONOR: Unrelated Umbilical Cord Blood: Any cord blood units with < 1.5 x 10^7 total nucleated cells per kilogram recipient weight
- DONOR: Unrelated Umbilical Cord Blood: Any cord blood units that have not passed donor screening for infectious disease markers as recommended by NMDP will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit; cord blood units are presumed to be CMV negative regardless of serologic testing due to passive transmission of maternal CMV antibodies
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00919503
Locations
| United States, Colorado | |
| Children's Hospital Colorado | |
| Aurora, Colorado, United States, 80045 | |
| United States, Oregon | |
| Oregon Health and Science University | |
| Portland, Oregon, United States, 97239 | |
| United States, Tennessee | |
| Vanderbilt University/Ingram Cancer Center | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Washington | |
| Seattle Children's Hospital | |
| Seattle, Washington, United States, 98105 | |
| Fred Hutch/University of Washington Cancer Consortium | |
| Seattle, Washington, United States, 98109 | |
| United States, Wisconsin | |
| Children's Hospital of Wisconsin | |
| Milwaukee, Wisconsin, United States, 53226 | |
Sponsors and Collaborators
Fred Hutchinson Cancer Center
medac GmbH
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
| Principal Investigator: | Lauri M. Burroughs | Fred Hutch/University of Washington Cancer Consortium |
Study Documents (Full-Text)
Documents provided by Lauri Burroughs, Fred Hutchinson Cancer Center:
Documents provided by Lauri Burroughs, Fred Hutchinson Cancer Center:
Study Protocol and Statistical Analysis Plan [PDF] May 21, 2020
| Responsible Party: | Lauri Burroughs, Associate Professor, Clinical Research Division, Fred Hutch; Director, Non-Malignant Transplant Program, Fred Hutchinson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00919503 |
| Other Study ID Numbers: |
2256.00 NCI-2010-01277 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2256.00 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) P30CA015704 ( U.S. NIH Grant/Contract ) RG2809001 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium ) |
| First Posted: | June 12, 2009 Key Record Dates |
| Results First Posted: | August 13, 2021 |
| Last Update Posted: | August 13, 2021 |
| Last Verified: | July 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
Keywords provided by Lauri Burroughs, Fred Hutchinson Cancer Center:
|
nonmalignant diseases nonmalignant inherited disorders primary immunodeficiency diseases primary immune deficiency disorders chronic granulomatous disease IPEX syndrome hemophagocytic lymphohistiocytosis Wiskott Aldrich Syndrome bone marrow failure syndromes Shwachman Diamond Syndrome |
Dyskeratosis Congenita Diamond Blackfan Anemia inborn errors of metabolism metabolic diseases hemoglobinopathies sickle cell disease thalassemia reduced intensity transplantation hematopoietic cell transplantation bone marrow transplantation umbilical cord blood transplantation |
Additional relevant MeSH terms:
|
Hematologic Diseases Disease Pathologic Processes Cyclosporine Mycophenolic Acid Methotrexate Fludarabine phosphate Fludarabine Treosulfan Busulfan Tacrolimus Cyclosporins Thymoglobulin Antilymphocyte Serum Abortifacient Agents, Nonsteroidal |
Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Dermatologic Agents Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Immunologic Factors Antirheumatic Agents Nucleic Acid Synthesis Inhibitors Calcineurin Inhibitors |